These findings suggested a role for NOTCH3 in driving the advancement and chemoresistance of NSCLC and supporting the potential role of NOTCH3 as a predictive biomarker for treatment response in this cohort of patients [126]. This evidence concerns the gene NOTCH3 and non-small cell lung carcinoma.